Insmed (INSM) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Insmed (INSM) over the past year, gaining 52.2% versus a loss of 28.9%. Over five years, INSM leads with a +388.5% price change compared with +60.9% for TAK. Takeda Pharmaceutical is the larger company by market cap ($69.55 billion vs $31.01 billion), about 2.2 times the size.
On valuation, Takeda Pharmaceutical trades at a lower forward P/E (41.1x vs 220.2x for Insmed). Takeda Pharmaceutical pays a dividend yielding 927.88%, while Insmed does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSM | TAK |
|---|---|---|
| Share price | $141.33 | $21.77 |
| Market cap | $31.01B | $69.55B |
| 1-day change | -2.17% | +1.68% |
| YTD return | -18.79% | +39.64% |
| 1-year return | -28.89% | +52.24% |
| 5-year return | +388.52% | +60.90% |
| P/E ratio (TTM) | — | 311.00 |
| Forward P/E | 220.18 | 41.08 |
| EPS (TTM) | $-2.81 | $0.07 |
| Dividend yield | 0.00% | 927.88% |
| Annual dividend | $0.00 | $202.00 |
| Revenue (latest FY) | $606.42M | — |
| Revenue growth (YoY) | +66.73% | — |
| Net income (latest FY) | $-1.28B | — |
| Gross margin | 79.73% | — |
| Operating margin | -205.59% | — |
| Net margin | -210.54% | — |
| 52-week high | $212.75 | $22.07 |
| 52-week low | $90.39 | $14.16 |
| Distance from 52-week high | -33.57% | -1.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +37.39% | +12.68% |
| Average volume | 3.09M | 2.73M |
| Shares outstanding | 219.38M | 3.19B |
| Employees | 1,664 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Takeda Pharmaceutical is about 2.2 times larger than Insmed by market value ($69.55B vs $31.01B).
- TAK has outperformed INSM by 81.1 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 0.00%).
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
INSM vs TAK FAQ
Which is bigger, Insmed or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $69.55B compared with $31.01B for Insmed (INSM).
Which stock has performed better over the past year, INSM or TAK?
TAK returned +52.24% over the past 12 months, compared with -28.89% for INSM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Insmed or Takeda Pharmaceutical?
Takeda Pharmaceutical pays a dividend yielding 927.88%, while Insmed does not currently pay a regular dividend.
Are Insmed and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.